Trefoil factor 3 predicts incident chronic kidney disease: A case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study

American Journal of Nephrology

Volumn 34, Issue 4, 2011, Pages 291-297

  Astor, Brad C ^a,b,c   Köttgen, Anna ^b,d   Hwang, Shih Jen ^e   Bhavsar, Nrupen ^a,b   Fox, Caroline S ^e,f   Coresh, Josef ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e FRAMINGHAM HEART STUDY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarkers; Kidney disease; Tubulointerstitual disease

Indexed keywords

CREATININE; HUMAN SERUM ALBUMIN; INTESTINAL TREFOIL FACTOR; TREFOIL FACTOR 3; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; URINE LEVEL;

ALBUMINURIA; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDES; PROBABILITY; RISK;

EID: 79961114370     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000330699     Document Type: Article

References (33)

1. Astor BC, Hallan SI, Miller ER III, et al.: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226-1234. (Pubitemid 351670638)
2. Shlipak MG, Sarnak MJ, Katz R, et al.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060. (Pubitemid 40664306)
3. Bash LD, Astor BC, Coresh J: Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010;55:31-41.
4. Fliser D, Kronenberg F, Kielstein JT, et al.: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461. (Pubitemid 41725064)
5. Fliser D, Kollerits B, Neyer U, et al.: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-2608.
6. Spanaus KS, Kronenberg F, Ritz E, et al.: Btype natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007;53:1264-1272. (Pubitemid 47020982)
7. Kronenberg F: Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009;5:677-689.
8. Bleyer AJ, Shemanski LR, Burke GL, et al.: Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000;57:2072-2079. (Pubitemid 30252299)
9. Fox CS, Larson MG, Leip EP, et al.: Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850. (Pubitemid 38543772)
10. Muntner P, Coresh J, Smith JC, et al.: Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int 2000;58:293-301. (Pubitemid 30429874)
11. James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 2010;375:1296-1309.
12. Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431. (Pubitemid 35340538)
13. Coons SJ: The FDA's critical path initiative: a brief introduction. Clin Ther 2009;31:2572-2573.
14. Podolsky DK, Lynch-Devaney K, Stow JL, et al.: Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:12230.
15. Taupin D, Podolsky DK: Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003;4:721-732. (Pubitemid 37082187)
16. ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
17. Wasserman BA, Astor BC, Sharrett AR, et al.: MRI measurements of carotid plaque in the Atherosclerosis Risk in Communities (ARIC) Study: methods, reliability and descriptive statistics. J Magn Reson Imaging 2010;31:406-415.
18. Bash LD, Coresh J, Kottgen A, et al.: Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol 2009;170:414-424.
19. Coresh J, Astor BC, McQuillan G, et al.: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39:920-929. (Pubitemid 34454210)
20. Stevens LA, Coresh J, Feldman HI, et al.: Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007;18:2749-2757. (Pubitemid 47531202)
21. Papp AC, Hatzakis H, Bracey A, et al.: ARIC hemostasis study. I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15-19. (Pubitemid 19092661)
22. Hoffmann W: Trefoil factor family (TFF) peptides and chemokine receptors: a promising relationship. J Med Chem 2009;52:6505-6510.
23. Hoffmann W: TFF (trefoil factor family) peptides; in Kastin AJ (ed): Handbook of Biologically Active Peptides. San Diego, Elsevier, 2006, pp 1147-1154.
24. Hoffmann W, Jagla W: Cell type specific expression of secretory TFF peptides: colocalization with mucins and synthesis in the brain. Int Rev Cytol 2002;213:147-181. (Pubitemid 34112918)
25. Wong WM, Poulsom R, Wright NA: Trefoil peptides. Gut 1999;44:890-895. (Pubitemid 29244230)
26. Rinnert M, Hinz M, Buhtz P, et al.: Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res 2010;339:639-647.
27. Hoffmann W: Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci 2005;62:2932-2938.
28. Pawar S, Kartha S, Toback FG: Differential gene expression in migrating renal epithelial cells after wounding. J Cell Physiol 1995;165:556-565. (Pubitemid 26004313)
29. Bonventre JV: Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003;14 (suppl 1):S55-S61.
30. Romih R, Koprivec D, Martincic DS, et al.: Restoration of the rat urothelium after cyclophosphamide treatment. Cell Biol Int 2001;25:531-537. (Pubitemid 32595151)
31. Veranic P, Romih R, Jezernik K: What determines differentiation of urothelial umbrella cells? Eur J Cell Biol 2004;83:27-34. (Pubitemid 38455604)
32. Hoffmann W: Regeneration of the gastric mucosa and its glands from stem cells. Curr Med Chem 2008;15:3133-3144.
33. Kouznetsova I, Peitz U, Vieth M, et al.: A gradient of TFF3 (trefoil factor family 3) peptide synthesis within the normal human gastric mucosa. Cell Tissue Res 2004;316:155-165. (Pubitemid 38658536)